Equities researchers at HC Wainwright initiated coverage on shares of Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) in a report issued on Thursday, Marketbeat.com reports. The firm set a “buy” rating and a $12.00 price target on the stock.
Several other brokerages have also issued reports on KAPA. Maxim Group assumed coverage on shares of Kairos Pharma in a report on Thursday, March 27th. They issued a “buy” rating and a $4.00 price target on the stock. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Kairos Pharma in a research note on Monday, March 31st.
Check Out Our Latest Stock Report on Kairos Pharma
Kairos Pharma Stock Up 12.8 %
About Kairos Pharma
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
See Also
- Five stocks we like better than Kairos Pharma
- What is diluted earnings per share (Diluted EPS)?
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- What is a Stock Market Index and How Do You Use Them?
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
